OCT East Coast 2026: Clinical Trial Innovation & Outsourcing

Key Takeaways

• OCT East Coast 2026 conference will be held May 13-14, 2026, in New Brunswick, New Jersey.
• The conference focuses on clinical operations, outsourcing, clinical technology, and innovation in clinical trials.
• Key presentations and panel discussions will cover topics such as trial resilience, outsourcing models, patient recruitment, and the role of AI in clinical trials.

The OCT East Coast 2026 conference is scheduled to take place on May 13-14, 2026, in New Brunswick, New Jersey. This event will bring together industry leaders to discuss clinical operations, outsourcing strategies, clinical technology advancements, and innovations shaping the future of clinical trials.

The conference is designed to provide insights into overcoming challenges in clinical trials, optimizing outsourcing models, enhancing patient recruitment, and leveraging technology to improve trial efficiency. With a focus on practical solutions and forward-thinking strategies, OCT East Coast 2026 aims to equip attendees with the knowledge and tools necessary to navigate the evolving landscape of clinical research.

Conference Overview

OCT East Coast 2026 is structured into two main streams: Clinical Operations and Outsourcing (Stream A), and Clinical Technology and Innovation (Stream B). The event will feature a mix of keynote panels, presentations, panel discussions, and interactive roundtable problem-solving sessions.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for general. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Day One Highlights

Day one of the conference will commence with a keynote panel on strengthening trial resilience by navigating FDA volatility and global uncertainty. This panel includes Revati Tatake (Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData) and Meghan Dierks (Executive Director of Advanced Analytics and Technology Assessment, Harvard Medical School). Mindy Hurd (Vice President and General Partner, ICON) will present on the next evolution of outsourcing models, including integrated partnership models and strategies for mitigating operational unpredictability. A panel discussion will address rebuilding trust across sponsors, CROs, and sites, emphasizing the importance of human factors in operational success. Additional sessions will cover topics such as artificial intelligence, accelerating start-up development, site relationships, and the use of wearables in clinical trials.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Day Two Highlights

Day two will feature a session led by patient advocate Mel Mann on navigating the processes between trials and commercialization to better understand patient expectations. John Gregg (Chairman and CEO, BalinBac Therapeutics) will lead a session on rebuilding patient recruitment in the US, addressing challenges related to trust, access, and site constraints. Panel discussions will delve into ownership and risk sharing between sponsors and vendors, the application of AI and automation in clinical trials, and the implementation of ICH E6(R3) guidelines. Roundtable problem-solving discussions will cover outsourcing models, sponsor-site relationships, digital tools, and strategies for addressing study startup bottlenecks.

Frequently Asked Questions

• When and where will OCT East Coast 2026 take place?

  The conference is scheduled for May 13-14, 2026, in New Brunswick, New Jersey.

• What are the main themes of the conference?

  The conference focuses on clinical operations, outsourcing, clinical technology, and innovation in clinical trials.

• Who are some of the featured speakers?

  Featured speakers include Revati Tatake (GlobalData), Meghan Dierks (Harvard Medical School), Mindy Hurd (ICON), Mel Mann (patient advocate), and John Gregg (BalinBac Therapeutics).

References

• OCT East Coast 2026: Overcoming FDA Volatility and Global Uncertainty

Related coverage

• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Why innovation alone is no longer enough in biopharma
• GLP-1 usage statistics show broad uptake and mixed clinical signals